Krystal Biotech (FRA:4KB) Inventories, Finished Goods : €2.0 Mil (As of Dec. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Krystal Biotech Inventories, Finished Goods?

Krystal Biotech's quarterly finished goods increased from Jun. 2024 (€1.5 Mil) to Sep. 2024 (€2.9 Mil) but then declined from Sep. 2024 (€2.9 Mil) to Dec. 2024 (€2.0 Mil).

Krystal Biotech's annual finished goods increased from Dec. 2022 (€0.0 Mil) to Dec. 2023 (€0.6 Mil) and increased from Dec. 2023 (€0.6 Mil) to Dec. 2024 (€2.0 Mil).

Krystal Biotech Inventories, Finished Goods Historical Data

The historical data trend for Krystal Biotech's Inventories, Finished Goods can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Krystal Biotech Inventories, Finished Goods Chart

Krystal Biotech Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Inventories, Finished Goods

Get a 7-Day Free Trial

0.58

2.03

Krystal Biotech Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Inventories, Finished Goods	Get a 7-Day Free Trial															0.58	0.15	1.52	2.89	2.03

Krystal Biotech Inventories, Finished Goods Calculation

The products in a manufacturer's inventory that are completed and are waiting to be sold.

Krystal Biotech Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Krystal Biotech Inc (FRA:4KB) » Definitions » Inventories, Finished Goods

Comparable Companies

Traded in Other Exchanges

KRYS:USA 4KB:Germany

Address

2100 Wharton Street, Suite 701, Pittsburgh, PA, USA, 15203

Website

https://www.krystalbio.com

Krystal Biotech Inc is engaged in the healthcare sector in the United States. It is focused on the development of easy-to-use, redosable gene therapies to improve the lives of patients living with debilitating diseases. The company used its proprietary gene therapy platform, STAR-D to develop treatments for rare or orphan dermatological indications caused by the absence of or a mutation in a single gene. It plans to leverage its platform to expand its pipeline to include other dermatological indications in the future. The company has one operating segment, which is the business of developing and commercializing pharmaceutical products.

Krystal Biotech Headlines

No Headlines